Cargando…
Label-Free Liquid Chromatography–Mass Spectrometry Proteomic Analysis of the Urinary Proteome for Measuring the Escitalopram Treatment Response From Major Depressive Disorder
Major depressive disorder (MDD) is a common mental disorder that can cause substantial impairments in quality of life. Clinical treatment is usually built on a trial-and-error method, which lasts ~12 weeks to evaluate whether the treatment is efficient, thereby leading to some inefficient treatment...
Autores principales: | Huan, Yuhang, Wei, Jing, Zhou, Jingjing, Liu, Min, Yang, Jian, Gao, Youhe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514635/ https://www.ncbi.nlm.nih.gov/pubmed/34658947 http://dx.doi.org/10.3389/fpsyt.2021.700149 |
Ejemplares similares
-
Comparative Proteomics Analysis of Pig Muscle Exudate through Label-Free Liquid Chromatography-Mass Spectrometry
por: Di Luca, Alessio, et al.
Publicado: (2023) -
Label-Free Liquid Chromatography–Mass Spectrometry Proteomic Analysis of Urinary Identification in Diabetic Vascular Dementia in a Han Chinese Population
por: Chen, Ruijuan, et al.
Publicado: (2021) -
Urinary proteome profiling for children with autism using data-independent acquisition proteomics
por: Meng, Wenshu, et al.
Publicado: (2021) -
Urinary biomarker discovery in gliomas using mass spectrometry-based clinical proteomics
por: Wu, Jianqiang, et al.
Publicado: (2020) -
Plasma proteomic analysis of systemic lupus erythematosus patients using liquid chromatography/tandem mass spectrometry with label-free quantification
por: Madda, Rashmi, et al.
Publicado: (2018)